Slide 1: Annual Shareholders Meeting
Annual Shareholders Meeting September 15, 2005 NASDAQ: TSTF Nursing Innovations sm A Division of TeamStaff Rx ® CONFIDENTIAL 1 TeamStaff Board of Directors Chairman, T. Stephen Johnson Vice-Chairman, Karl W. Dieckmann Directors Ron Aldrich Peter Black Martin J. Delaney Ben Dyer Rocco J. Marano T. Ke
Slide 2: TeamStaff Management
TeamStaff Management T. Kent Smith, President and CEO Rick Filippelli, Vice President and CFO Greg Haygood, Chief Technology Officer James D. Houston, Vice President, General Counsel and Secretary Peter Rosen, Vice President, Human Resources Martin J. Delaney, Senior Vice-President Timothy Nieman, S
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Federal Securities Laws. TeamStaff's actual results could differ materially from those described in such forward-looking statements as a result of certain risk factors, including but not limited to:
Slide 4: Company Vision: Reposition TeamStaff As A Top Dozen '1-Stop Shop'
Company Vision: Reposition TeamStaff As A Top Dozen ‘1-Stop Shop’ Healthcare Staffing Provider To The Commercial & Govt. Sectors Service Offering Allied Health/Pharmacy Nurse Travel Nursing Innovations sm A Division of TeamStaff Rx ® (13-week contract) Per Diem Nursing Innovations sm (daily/wkly) A
Slide 5: Overview of Brands
Overview of Revenues of $27.5 million for TTM ended June 30, 2005 A Leading National Provider of Allied ‘Travel’ Health Personnel and Permanent Placement Focus on specialty areas that are critical for hospital—radiological techs, cardiovascular techs, ultrasound techs, radiation therapists, nuclear
Slide 6: Overview of RS Staffing and DSi Payroll
Overview of $41 million in Revenues for FYE December 31, 2004 Adjusted (owner takeouts) Pre-Tax Income of approximately $2.0 million for FYE 2004 Healthcare and Clerical Provided to the Government – VA & GSA (Government Services Administration) Government contracts are typically awarded for 3-5 year
Slide 7: Company Developments: The Turnaround
Company Developments: The Turnaround Built New & Experienced Leadership Team General Staffing and Healthcare Staffing Industry Experience Public Company/Executive Management Experience Sold PEO to Gevity in November 2003 PEO Was Low Margin, Capital Intensive Business Provided Capital to Focus on Cor
Slide 8: Industry Overview: Attractive Future Dynamics
Industry Overview: Past 30 months have Been “Stormy,” but Analysts forecast Rebound in 2nd Half of CY2005 U.S. Healthcare Staffing Market Change vs. Prior Year +27% +25% -8.8% -2% +5% +7% CONFIDENTIAL Source: Staffing Industry Analysts, Inc. estimates and projections 15 Industry Overview: Attractive
Slide 9: Industry Overview: Healthcare Staffing Segments
Industry Overview: TeamStaff Rx Participates in Three High-Margin Healthcare Staffing Industry Segments of a $11.2 billion Industry* Per Diem Nursing $4.7 Locum Tenens (Physicians) $1.1 Allied Health/Pharmacy/Other Travel Nursing $3.7 $1.7 *Source: Staffing Industry Analysts, Inc. estimates and proj
Slide 10: Trailing Twelve Month Income Statement
Trailing Twelve Month Income Statement Period Ended 6/30/05 (unaudited) Proforma TeamStaff RS Staffing Total Adjustments Synergies Combined ($ in Thousands) Total Revenues $ 40,716 $ 43,453 $ 84,169 $ 84,169 Cost of Revenues 30,853 37,370 68,223 (435) 67,788 Gross Profit 9,863 6,083 15,947 435 16,38
Slide 11: Summary Of TeamStaff Opportunities
Corporate Overhead 15% $1.48 ($ in Millions) $1.26 Employee Related Other SG&A 3Q04 3Q05* *Excludes Workers’ Compensation Receivable Adjustment CONFIDENTIAL 21 Summary Of TeamStaff Opportunities Long-Term Growth of Healthcare Staffing Industry Industry expected to Rebound in 2005-6 Both Acquisitions
Slide 12: EBITDA reconciliation
TeamStaff EBITDA reconciliation TTM ended June 30, 2005 ($ in thousands) <TABLE> TeamStaff RS Staffing Total Proforma Synergies Combined Adjustments Operating Income (Loss) $ (3,295) $ 507 $ (2,787) $ 1,396 $ 747 $ (645) Add: Depreciation 538 138 677 677 EBITDA $ (2,757) $ 646 $ (2,111) $ 32 </TABLE